1. Home
  2. OMER vs RES Comparison

OMER vs RES Comparison

Compare OMER & RES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Omeros Corporation

OMER

Omeros Corporation

N/A

Current Price

$19.89

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Logo RPC Inc.

RES

RPC Inc.

N/A

Current Price

$6.02

Market Cap

1.3B

Sector

Energy

ML Signal

N/A

Company Overview

Basic Information
Metric
OMER
RES
Founded
1994
1984
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Oilfield Services/Equipment
Sector
Health Care
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.3B
IPO Year
2008
1995

Fundamental Metrics

Financial Performance
Metric
OMER
RES
Price
$19.89
$6.02
Analyst Decision
Buy
Hold
Analyst Count
3
5
Target Price
★ $27.50
$6.40
AVG Volume (30 Days)
1.3M
★ 1.9M
Earning Date
11-12-2026
10-29-2026
Dividend Yield
N/A
★ 2.67%
EPS Growth
★ 98.15
N/A
EPS
★ 0.77
0.06
Revenue
$29,868,000.00
★ $41,919,000,000.00
Revenue This Year
N/A
$13.23
Revenue Next Year
$73.58
$0.79
P/E Ratio
★ $24.83
$100.00
Revenue Growth
N/A
★ 2216.21
52 Week Low
$4.06
$4.18
52 Week High
$21.24
$8.16

Technical Indicators

Market Signals
Indicator
OMER
RES
Relative Strength Index (RSI) 59.63 51.22
Support Level $18.00 $5.97
Resistance Level $21.24 $6.18
Average True Range (ATR) 0.76 0.18
MACD -0.12 0.03
Stochastic Oscillator 55.90 71.88

Price Performance

Historical Comparison
OMER
RES

About OMER Omeros Corporation

Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.

About RES RPC Inc.

RPC Inc is an oilfield services company. It provides specialized oilfield services and equipment to independent and oil and gas companies engaged in the exploration, production, and development of oil and gas properties throughout the United States. Its operating segment includes Technical Services and Support Services. The Technical Services segment, which generates maximum revenue, comprises service lines that generate revenue based on equipment, personnel, or materials at the well site and are closely aligned with completion and production activities of the customers. The Support Services segment comprises service lines that generate revenue from services and equipment offered off the well site and are closely aligned with the customers' drilling activities.

Share on Social Networks: